Ikei S. Kobayashi

497 citations

24 papers · 337 indexed · h-index 9

Nephrology top 10%
- Renal Diseases and Glomerulopathies 6
Oncology
- HER2/EGFR in Cancer Research 4
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 6
Immunology
- T-cell and B-cell Immunology 3
Cancer Research
Molecular Biology
- RNA modifications and cancer 4
- Glycosylation and Glycoproteins Research 2
Gastroenterology
- Celiac Disease Research and Management 3
Virology
- HIV Research and Treatment 2

Co-authors: Susumu Kobayashi Daniel B. Costa Fumiaki Nogaki Shigeki Miyawaki Tadashi Kamata Eri Muso Haruyoshi Yoshida Masanori Fujii
Cited by: Nephrology Oncology Pulmonary and Respiratory Medicine
Journals: Blood (1 paper)The Journal of Immunology (1 paper)Cancer Research (3 papers)
Partner nations: Japan United States Singapore

In The Last Decade

Ikei S. Kobayashi

23 papers receiving 334 citations

Peers

Countries citing papers authored by Ikei S. Kobayashi

Since Specialization

Citations

This map shows the geographic impact of Ikei S. Kobayashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ikei S. Kobayashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ikei S. Kobayashi more than expected).

Fields of papers citing papers by Ikei S. Kobayashi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ikei S. Kobayashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ikei S. Kobayashi. The network helps show where Ikei S. Kobayashi may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ikei S. Kobayashi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ikei S. Kobayashi Line = papers co-authored together Ikei S. Kobayashi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer Cell Death and Disease ·Motohiro Izumi,Masanori Fujii,Ikei S. Kobayashi,Vivian Ho,Yukie Kashima,Hibiki Udagawa,Daniel B. Costa,Susumu Kobayashi	2024	7
2	TIP60 is required for tumorigenesis in non‐small cell lung cancer Cancer Science ·Daisuke Shibahara,Naoki Akanuma,Ikei S. Kobayashi,Eunyoung Heo,Mariko Ando,Masanori Fujii,Feng Jiang,P. Nicholas Prin,Gilbert Pan,Kwok‐Kin Wong,Daniel B. Costa,Deepak Bararia,Daniel G. Tenen,Hideo Watanabe,Susumu Kobayashi	2023	14
3	The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors JTO Clinical and Research Reports ·Ikei S. Kobayashi,William O. Shaffer,Hollis Viray,Deepa Rangachari,Paul A. VanderLaan,Susumu Kobayashi,Daniel B. Costa	2023	6
4	EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors Lung Cancer ·William O. Shaffer,Ikei S. Kobayashi,Daniel Sentana‐Lledo,Shriram K. Sundararaman,Meghan Lee,Deepa Rangachari,Paul A. VanderLaan,Susumu Kobayashi,Daniel B. Costa	2023	3
5	An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1 British Journal of Cancer ·Fareesa Aftab,Alice Rodriguez-Fuguet,Luis Silva,Ikei S. Kobayashi,Jiao Sun,Katerina Politi,Elena Levantini,Wei Zhang,Susumu Kobayashi,Wen Cai Zhang	2023	8
6	Abstract 451: AICAR targets oncogenic signaling pathways of MUC1-CT Cancer Research ·Fareesa Aftab,Alice Rodriguez-Fuguet,Luís F.O. Silva,Ikei S. Kobayashi,Jiao Sun,Katerina Politi,Elena Levantini,Wei Zhang,Susumu Kobayashi,Wen Cai Zhang	2023	1
7	Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cancer Research ·Yukie Kashima,Daisuke Shibahara,Ayako Suzuki,Kyoko Muto,Ikei S. Kobayashi,David Plotnick,Hibiki Udagawa,Hiroki Izumi,Yuji Shibata,Kosuke Tanaka,Masanori Fujii,Akihiro Ohashi,Masahide Seki,Kōichi Goto,Katsuya Tsuchihara,Yutaka Suzuki,Susumu Kobayashi	2021	49
8	NAD Modulates DNA Methylation and Cell Differentiation Cells ·Simone Ummarino,Clinton Hausman,Giulia Gaggi,Lucrezia Rinaldi,Mahmoud A. Bassal,Yanzhou Zhang,Andy Joe Seelam,Ikei S. Kobayashi,Marta Borchiellini,Alexander K. Ebralidze,Barbara Ghinassi,Bon Q. Trinh,Susumu Kobayashi,Annalisa Di Ruscio	2021	16
9	Alternative splicing of APOBEC3D generates functional diversity and its role as a DNA mutator International Journal of Hematology ·Hisashi Takei,Hirofumi Fukuda,Gilbert Pan,Hiroyuki Yamazaki,Tadahiko Matsumoto,Yasuhiro Kazuma,Masanori Fujii,Sohei Nakayama,Ikei S. Kobayashi,Keisuke Shindo,Riu Yamashita,Kotaro Shirakawa,Akifumi Takaori‐Kondo,Susumu Kobayashi	2020	4
10	Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations JTO Clinical and Research Reports ·Pedro Eduardo Nascimento Silva Vasconcelos,Ikei S. Kobayashi,Susumu Kobayashi,Daniel B. Costa	2020	17
11	EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors JTO Clinical and Research Reports ·Pedro Eduardo Nascimento Silva Vasconcelos,Carol Gergis,Hollis Viray,Andreas Varkaris,Masanori Fujii,Deepa Rangachari,Paul A. VanderLaan,Ikei S. Kobayashi,Susumu Kobayashi,Daniel B. Costa	2020	53
12	Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation Bioorganic & Medicinal Chemistry Letters ·Sridhar Radhakrishnan,Riyaz Syed,Hisashi Takei,Ikei S. Kobayashi,Eugene Nakamura,Farheen Sultana,Ähmed Kamal,Daniel G. Tenen,Susumu Kobayashi	2019	0
13	Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBPα Molecules ·Sridhar Radhakrishnan,Hisashi Takei,Riyaz Syed,Ikei S. Kobayashi,Liu Bee Hui,Ähmed Kamal,Daniel G. Tenen,Susumu Kobayashi	2018	6
14	Roles of coagulation pathway and factor Xa in rat mesangioproliferative glomerulonephritis Laboratory Investigation ·Keiko Nomura,Ning Liu,Kojiro Nagai,Takamichi Hasegawa,Ikei S. Kobayashi,Fumiaki Nogaki,Misa Tanaka,Hidenori Arai,Atsushi Fukatsu,Toru Kita,Takahiko Ono	2006	25
15	Chromosomal mapping of hyperserum IgA and glomerular IgA deposition in a high IgA (HIGA) strain of DdY mice Kidney International ·Fumiaki Nogaki,Emi Oida,Tadashi Kamata,Ikei S. Kobayashi,Keiko Nomura,Katsuo Suyama,Sachiko Tahara,Takahiko Ono,Shigeki Miyawaki,Tadao Serikawa,Haruyoshi Yoshida,Toru Kita,Eri Muso	2005	6
16	Quantitative trait loci (QTL) analysis reveals a close linkage between the hinge region and trimeric IgA dominancy in a high IgA strain (HIGA) of ddY mice European Journal of Immunology ·Emi Oida,Fumiaki Nogaki,Ikei S. Kobayashi,Tadashi Kamata,Takahiko Ono,Shigeki Miyawaki,Tadao Serikawa,Haruyoshi Yoshida,Toru Kita,Eri Muso	2004	8
17	Role of transforming growth factor‐β/Smad signalling pathway in enhanced production of glomerular extracellular matrix in IgA nephropathy of high‐serum‐IgA ddY mice Nephrology ·Yutaka Kanamaru,Atsuhito Nakao,Chisei Ra,Ko Okumura,Eri Muso,Hideoki Ogawa,Ikei S. Kobayashi,Satoshi Horikoshi,Yasukiko Tomino	2002	4
18	Up-Regulated TGF-β mRNA Expression in Splenic T Cells of High IgA-Prone Mice: A Murine Model of IgA Nephropathy with Glomerulosclerosis The Nephron journals/Nephron journals ·Atsushi Oyama,Eri Muso,Takahiko Ono,Hiroyuki Matsushima,Masatomo Yashiro,Katsuo Suyama,Tadashi Kamata,Fumiaki Nogaki,Ikei S. Kobayashi,Shigeki Miyawaki,Haruyoshi Yoshida,Shigetake Sasayama	2001	4
19	Increased Frequency of Surface IgA-Positive Plasma Cells in the Intestinal Lamina Propria and Decreased IgA Excretion in Hyper IgA (HIGA) Mice, a Murine Model of IgA Nephropathy with Hyperserum IgA The Journal of Immunology ·Tadashi Kamata,Fumiaki Nogaki,Sidonia Fagarasan,Toshio Sakiyama,Ikei S. Kobayashi,Shigeki Miyawaki,Koichi Ikuta,Eri Muso,Haruyoshi Yoshida,Shigetake Sasayama,Tasuku Honjo	2000	67
20	Interleukin 12 induces crescentic glomerular lesions in a high IgA strain of ddY mice, independently of changes in IgA deposition Nephrology Dialysis Transplantation ·Fumiaki Nogaki,Eri Muso,Ikei S. Kobayashi,Hitoshi Kusano,Kiichi Shirakawa,Tadashi Kamata,Atsushi Oyama,Takahiko Ono,Shigeki Miyawaki,Haruyoshi Yoshida,Shigetake Sasayama	2000	22

About Ikei S. Kobayashi

Ikei S. Kobayashi is a scholar working on Nephrology, Gastroenterology and Virology, having authored 24 papers that have together received 337 indexed citations. Recurring topics across this work include Renal Diseases and Glomerulopathies (6 papers), Lung Cancer Treatments and Mutations (6 papers), RNA modifications and cancer (4 papers), HER2/EGFR in Cancer Research (4 papers), Celiac Disease Research and Management (3 papers), T-cell and B-cell Immunology (3 papers), Glycosylation and Glycoproteins Research (2 papers) and HIV Research and Treatment (2 papers). The work is most often cited by research in Nephrology (54 citations), Oncology (109 citations) and Pulmonary and Respiratory Medicine (122 citations). Ikei S. Kobayashi has collaborated with scholars based in Japan, United States and Singapore. Frequent co-authors include Susumu Kobayashi, Daniel B. Costa, Fumiaki Nogaki, Shigeki Miyawaki, Tadashi Kamata, Eri Muso, Haruyoshi Yoshida, Masanori Fujii, Shigetake Sasayama and Hollis Viray. Their work appears in journals such as Blood, The Journal of Immunology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact